Tools
Tools
Milligan, Rachael, Daher, Andre, Villanueva, Gemma, Bergman, Hanna and Graves, Patricia M (2020) 'Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax'. The Cochrane Database of Systematic Reviews, Vol 8, CD012656.
|
Text
Milligan_et_al-2020-Cochrane_Database.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. Download (885kB) | Preview |
Abstract
Background
Plasmodium vivax liver stages (hypnozoites) may cause relapses, prolonging morbidity, and impeding malaria control and elimination. The World Health Organization (WHO) recommends three schedules for primaquine: 0.25 mg/kg/day (standard), or 0.5 mg/kg/day (high standard) for 14 days, or 0.75 mg/kg once weekly for eight weeks, all of which can be difficult to complete. Since primaquine can cause haemolysis in individuals with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, clinicians may be reluctant to prescribe primaquine without G6PD testing, and recommendations when G6PD status is unknown must be based on an assessment of the risks and benefits of prescribing primaquine. Alternative safe and efficacious regimens are needed.
| Item Type: | Article |
|---|---|
| Subjects: | QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials QX Parasitology > Protozoa > QX 135 Plasmodia WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria |
| Faculty: Department: | Clinical Sciences & International Health > Clinical Sciences Department |
| Digital Object Identifer (DOI): | https://doi.org/10.1002/14651858.CD012656.pub3 |
| Depositing User: | Christianne Esparza |
| Date Deposited: | 07 Oct 2020 12:09 |
| Last Modified: | 11 Nov 2020 11:47 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/15776 |
Statistics
Actions (login required)
 |
Edit Item |